

# Ina Andrassy Eilertsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9190386/publications.pdf>

Version: 2024-02-01

16  
papers

810  
citations

840776

11  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. <i>Molecular Cancer</i> , 2017, 16, 116.	19.2	232
2	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806.	7.0	177
3	Multilevel genomics of colorectal cancers with microsatellite instability" clinical impact of JAK1 mutations and consensus molecular subtype 1. <i>Genome Medicine</i> , 2017, 9, 46.	8.2	71
4	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. <i>Cancer Letters</i> , 2017, 385, 150-159.	7.2	70
5	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	7.0	68
6	Long noncoding RNA <i>MIR31HG</i> is a <i>bona fide</i> prognostic marker with colorectal cancer cell-intrinsic properties. <i>International Journal of Cancer</i> , 2019, 144, 2843-2853.	5.1	33
7	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. <i>Npj Genomic Medicine</i> , 2021, 6, 59.	3.8	29
8	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 841-847.	5.1	26
9	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. <i>EBioMedicine</i> , 2020, 59, 102923.	6.1	22
10	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. <i>Oncogenesis</i> , 2019, 8, 35.	4.9	19
11	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. <i>Molecular Oncology</i> , 2017, 11, 1156-1171.	4.6	15
12	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. <i>Cancer Letters</i> , 2020, 469, 246-255.	7.2	12
13	Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. <i>Modern Pathology</i> , 2018, 31, 1694-1707.	5.5	11
14	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000523.	4.5	11
15	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. <i>Genome Medicine</i> , 2021, 13, 143.	8.2	10
16	The expressed mutational landscape of microsatellite stable colorectal cancers. <i>Genome Medicine</i> , 2021, 13, 142.	8.2	4